Astria Therapeutics, INC Form 4 insider transactions

Astria Therapeutics CEO Jill C. Milne was granted stock options for 761,000 shares on March 21, 2025, according to a Form 4 filing.

Andrea Matthews, Chief Business Officer of Astria Therapeutics, reports the grant of stock options for 262,500 shares.

Andrew Komjathy, Chief Commercial Officer of Astria Therapeutics, received stock options for 225,000 shares on March 21, 2025.

Benjamin Harshbarger, Chief Legal Officer of Astria Therapeutics, was granted stock options for 262,500 shares on March 21, 2025.

Noah Clauser, CFO of Astria Therapeutics, reports the acquisition of stock options.

Christopher Morabito, Chief Medical Officer of Astria Therapeutics, received stock options for 262,500 shares on March 21, 2025, vesting over four years.

Anthony Gregg Lapointe, a director of Astria Therapeutics, acquired stock options for 14,100 shares at an exercise price of $9.18 on June 5, 2024.

Joanne T. Beck, a director of Astria Therapeutics, Inc., reported the acquisition of stock options on June 5, 2024.

Director Jonathan Violin reports the grant of stock options in Astria Therapeutics, Inc.

Fred Callori, a director of Astria Therapeutics, acquired 14,100 stock options on June 5, 2024.

Director Michael Kishbauch of Astria Therapeutics, Inc. reports the acquisition of stock options on June 5, 2024.

Director Hugh Cole reports the acquisition of stock options in Astria Therapeutics, Inc.

Director Kenneth Bate of Astria Therapeutics, Inc. reports the acquisition of stock options on June 5, 2024.

Director Sunil Agarwal of Astria Therapeutics, Inc. received stock options for 28,200 shares on April 8, 2024.

Christopher Morabito, Chief Medical Officer of Astria Therapeutics, exercised stock options and sold 10,000 shares of common stock on April 1, 2024, under a pre-arranged trading plan.